Theragen Etex Co Ltd
KOSDAQ:066700
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
2 460
3 315
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| KR |
T
|
Theragen Etex Co Ltd
KOSDAQ:066700
|
110.2B KRW |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
954.9B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
546.2B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
268.4B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
209.9B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
219B CHF |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.7T DKK |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
265.4B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
147.6B USD |
Loading...
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
94.4B EUR |
Loading...
|
Market Distribution
| Min | -168 471.3% |
| 30th Percentile | -2.9% |
| Median | 1.9% |
| 70th Percentile | 5.8% |
| Max | 21 012.5% |
Other Profitability Ratios
Theragen Etex Co Ltd
Glance View
THERAGEN ETEX Co., Ltd. engages in the manufacture and sale of pharmaceutical products and in the provision of genome sequencing services. The company is headquartered in Ansan, Gyeonggi-Do. The company went IPO on 2004-05-27. is a Korea-based company engaged in the industrial equipment business, healthcare and genome business and pharmaceutical business. The firm operates its business through three divisions: flat panel display (FPD) manufacturing equipment division, which provides loading and unloading systems, printed circuit board (PCB) bonding systems, battery washing lines and laser systems; healthcare and genome division engages in the provision of genome analysis services and others, and pharmaceutical division engages in the manufacture of digestive system remedies, antibiotics, remedies for fever, circulatory system remedies, respiration system remedies, treatment for chronic hepatitis, diabetes remedies, psychotropic agents, osteoporosis treatments and others.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Theragen Etex Co Ltd is -17.3%, which is below its 3-year median of -0.9%.
Over the last 3 years, Theragen Etex Co Ltd’s Net Margin has decreased from 3.5% to -17.3%. During this period, it reached a low of -17.4% on Jun 30, 2025 and a high of 12.1% on Dec 31, 2023.